You have successfully logged out.
October 15, 2025
B. Braun Launches Midazolam in 0.8% Sodium Chloride Injection with Enhanced Safety and Usability Features
BETHLEHEM, PA – October 15, 2025 – B. Braun Medical Inc. (B. Braun), a recognized leader in infusion therapy and pharmaceutical manufacturing, announced the launch of Midazolam in 0.8% Sodium Chloride Injection in the U.S. market. The preservative-free injections will be offered in two strengths — 50 mg in 50 mL and 100 mg in 100 mL. Both strengths are packaged in IV bags that are not made with DEHP, PVC or natural rubber latex, placing a priority on patient and environmental safety.
The Midazolam in 0.8% Sodium Chloride Injections has a 36-month shelf life, providing healthcare facilities with greater flexibility in inventory management and long-term storage. In addition, each bag incorporates a 2D enhanced barcode that includes the National Drug Code (NDC) number, lot number and expiration date. These updates are part of B. Braun’s ongoing commitment to making workflows safer and more efficient for clinicians—while helping reduce the likelihood of medication errors.
“Midazolam in 0.8% Sodium Chloride Injection marks another meaningful step in our commitment to delivering high-quality, patient-focused solutions,” said Jeremy Greene, Sr. Director of Marketing, IV Fluids and Pharma Injectables. “With its preservative-free formulation, barcode technology and packaging not made with DEHP, PVC or natural rubber latex, this product is thoughtfully designed to meet the needs of both patients and healthcare providers.”
With the release of Midazolam in 0.8% Sodium Chloride Injection, B. Braun continues to expand its portfolio of essential injectable medications, reinforcing its role as a trusted partner in advancing healthcare safety and reliability.
For additional information, please see full Prescribing Information.
Important Safety Information
About B. Braun
B. Braun Medical Inc. (B. Braun) is a leader in smart infusion therapy and safe and effective pharmacy products, patient and provider safety, and sustainable health solutions. Our purpose is to help providers constantly improve patient satisfaction and outcomes. With products and services created to help healthcare professionals focus on what matters most—their patients—we’re uniquely positioned to help health systems succeed now and in the future. B. Braun is headquartered in Bethlehem, Pennsylvania and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. The company employs 8,500 people at over 30 locations across North America.
Globally, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, explore our website.